X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with Sterling Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs STERLING BIOTECH - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA STERLING BIOTECH SANOFI INDIA/
STERLING BIOTECH
 
P/E (TTM) x 31.0 -1.8 - View Chart
P/BV x 5.5 0.1 7,891.0% View Chart
Dividend Yield % 1.6 0.0 -  

Financials

 SANOFI INDIA   STERLING BIOTECH
EQUITY SHARE DATA
    SANOFI INDIA
Dec-16
STERLING BIOTECH
Dec-13
SANOFI INDIA/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs4,56011 43,428.6%   
Low Rs4,4003 129,411.8%   
Sales per share (Unadj.) Rs1,028.526.8 3,836.7%  
Earnings per share (Unadj.) Rs129.0-15.0 -862.2%  
Cash flow per share (Unadj.) Rs186.0-5.5 -3,404.4%  
Dividends per share (Unadj.) Rs68.000-  
Dividend yield (eoy) %1.50-  
Book value per share (Unadj.) Rs753.654.9 1,373.2%  
Shares outstanding (eoy) m23.03267.87 8.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.40.3 1,680.1%   
Avg P/E ratio x34.7-0.5 -7,476.0%  
P/CF ratio (eoy) x24.1-1.3 -1,893.4%  
Price / Book Value ratio x5.90.1 4,694.3%  
Dividend payout %52.70-   
Avg Mkt Cap Rs m103,1741,862 5,542.0%   
No. of employees `0003.61.4 267.6%   
Total wages/salary Rs m3,592547 656.9%   
Avg. sales/employee Rs Th6,537.75,303.3 123.3%   
Avg. wages/employee Rs Th991.4403.8 245.5%   
Avg. net profit/employee Rs Th819.8-2,959.0 -27.7%   
INCOME DATA
Net Sales Rs m23,6867,181 329.9%  
Other income Rs m70843 1,662.0%   
Total revenues Rs m24,3947,223 337.7%   
Gross profit Rs m5,281947 557.7%  
Depreciation Rs m1,3132,543 51.6%   
Interest Rs m154,377 0.3%   
Profit before tax Rs m4,661-5,931 -78.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,691-1,924 -87.9%   
Profit after tax Rs m2,970-4,007 -74.1%  
Gross profit margin %22.313.2 169.1%  
Effective tax rate %36.332.4 111.8%   
Net profit margin %12.5-55.8 -22.5%  
BALANCE SHEET DATA
Current assets Rs m15,67314,335 109.3%   
Current liabilities Rs m6,67849,809 13.4%   
Net working cap to sales %38.0-494.0 -7.7%  
Current ratio x2.30.3 815.5%  
Inventory Days Days76403 18.8%  
Debtors Days Days22171 13.1%  
Net fixed assets Rs m8,09855,432 14.6%   
Share capital Rs m230268 86.0%   
"Free" reserves Rs m17,08813,935 122.6%   
Net worth Rs m17,35614,701 118.1%   
Long term debt Rs m09,478 0.0%   
Total assets Rs m25,40073,988 34.3%  
Interest coverage x311.7-0.4 -87,821.8%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x0.90.1 960.8%   
Return on assets %11.80.5 2,346.2%  
Return on equity %17.1-27.3 -62.8%  
Return on capital %26.9-6.4 -419.3%  
Exports to sales %24.525.9 94.6%   
Imports to sales %28.00.2 16,467.7%   
Exports (fob) Rs m5,8011,860 311.9%   
Imports (cif) Rs m6,62712 54,319.7%   
Fx inflow Rs m7,1451,860 384.2%   
Fx outflow Rs m6,84625 27,505.0%   
Net fx Rs m2991,835 16.3%   
CASH FLOW
From Operations Rs m3,2261,719 187.7%  
From Investments Rs m-1,555-3,148 49.4%  
From Financial Activity Rs m-1,8181,426 -127.5%  
Net Cashflow Rs m-147-3 4,323.5%  

Share Holding

Indian Promoters % 0.0 33.9 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 0.0 -  
FIIs % 14.6 9.9 147.5%  
ADR/GDR % 0.0 16.9 -  
Free float % 10.5 39.3 26.7%  
Shareholders   15,184 21,482 70.7%  
Pledged promoter(s) holding % 0.0 55.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   CIPLA  PFIZER  ALEMBIC PHARMA  SHASUN PHARMA  NOVARTIS  

Compare SANOFI INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Of Pharma Drug Approvals, Global Updates, Oil Prices, and Top Stocks in Action Today(Pre-Open)

Indian share markets snapped their losing streak seen during last week and closed their Wednesday session on a positive note.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

Aug 4, 2017

The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Aug 16, 2017 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA - STRIDES SHASUN LTD COMPARISON

COMPARE SANOFI INDIA WITH

MARKET STATS